246 related articles for article (PubMed ID: 21122637)
1. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
[TBL] [Abstract][Full Text] [Related]
2. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
3. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
6. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
10. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
11. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
[TBL] [Abstract][Full Text] [Related]
12. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of laropiprant on niacin-induced flushing.
Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
[TBL] [Abstract][Full Text] [Related]
14. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Ballantyne C; Gleim G; Liu N; Sisk CM; Johnson-Levonas AO; Mitchel Y
J Clin Lipidol; 2012; 6(3):235-43. PubMed ID: 22658147
[TBL] [Abstract][Full Text] [Related]
15. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
16. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
17. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM
Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632
[TBL] [Abstract][Full Text] [Related]
18. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
Ix JH; Ganjoo P; Tipping D; Tershakovec AM; Bostom AG
Am J Kidney Dis; 2011 Jun; 57(6):963-5. PubMed ID: 21496982
[No Abstract] [Full Text] [Related]
19. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.
McKenney J; Bays H; Gleim G; Mitchel Y; Kuznetsova O; Sapre A; Sirah W; Maccubbin D
J Clin Lipidol; 2015; 9(3):313-25. PubMed ID: 26073389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
